[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acne\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acne":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,24,0,[8,56,84,110,133,171,193,213,245,271,295,319,341,362,384,405,425,446,470,490,519,542,564,589],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":4},"100629926","a-randomised-controlled-trial-of-eprom-guided-flexible-scheduling-in-dermatology-100629926",false,"NCT07481019","A Randomised Controlled Trial of ePROM-Guided Flexible Scheduling in Dermatology","Inclusion Criteria:\n\n* Dermatology outpatients otherwise due for a follow-up appointment within six months.\n* Ability to independently navigate and complete ePROMs.\n* Ability to provide informed consent (including parental consent for minors).\n\nExclusion Criteria:\n\n* Patients who require fixed or scheduled in-person visits, including those needing skin cancer surveillance, bedside procedures (e.g., liquid nitrogen therapy), surgical interventions, or routine blood tests for immunosuppressive therapy.","ALL","16 Years",{"count":18,"type":19},250,"ESTIMATED","INTERVENTIONAL",[22],"NA","The goal of this clinical trial is to evaluate whether an electronic patient-reported outcome measure (ePROM)-guided flexible scheduling system can improve outpatient clinic resource utilisation in patients attending dermatology outpatient clinics for routine follow-up. The main questions it aims to answer are:\n\n* Does the intervention reduce the number of actualised outpatient visits over 12 months compared with standard fixed scheduling?\n* Does the intervention group achieve higher adherence to monthly ePROM monitoring, as measured by the proportion of completed ePROM submissions?",[25,26,27,28,29],"Chronic Dermatological Conditions","Eczema","Urticaria","Psoriasis","Acne",[31,32,33,34,35,36,37,38,39,40,41,42,43],"dermatology","flexible scheduling","patient initiated follow up","electronic patient-reported outcomes","ePROMs","Bayesian decision support","outpatient care","health services research","randomised controlled trial","implementation science","healthcare utilisation","appointment no-shows","value-based care","NOT_YET_RECRUITING","2026-06-29",{"date":47,"type":48},"2026-07-01","ACTUAL",{"date":50,"type":19},"2026-09",{"date":52,"type":19},"2029-12",{"name":54,"class":55},"National University Hospital, Singapore","OTHER",{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":15,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":4,"studyType":20,"phases":67,"briefSummary":68,"conditions":69,"keywords":70,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":80,"locationsCount":83},"100602746","a-clinical-trial-to-investigate-the-efficacy-and-safety-of-genlabs-social-renew-on-improving-acne-symptoms-and-skin-repair-among-healthy-adults-100602746","NCT07127523","A Clinical Trial to Investigate the Efficacy and Safety of GenLabs' Social Renew on Improving Acne Symptoms and Skin Repair Among Healthy Adults","A Randomized, Triple-blind, Placebo Controlled, Parallel Virtual Clinical Trial to Investigate the Efficacy and Safety of GenLabs' Social Renew on Improving Acne Symptoms and Skin Repair Among Healthy Adults","Inclusion Criteria:\n\n1. Males and females between 18 and 65 years of age inclusive\n2. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening\n\n   Or,\n\n   Individuals of child-bearing potential must self-report confirmation they are not pregnant, do not plan to become pregnant, and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:\n   * Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)\n   * Double-barrier method\n   * Intrauterine devices\n   * Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)\n   * Vasectomy of partner at least 6 months prior to screening\n   * Abstinence\n3. Experience acne on facial skin that is visible to the participant and is confirmed by the QI at screening and at baseline\n4. Willingness to complete questionnaires and diaries associated with the study, to capture and upload photos, and to complete all virtual visits\n5. Willingness to maintain the same skincare regimen throughout the study, including maintaining make-up routine without the addition of new make-up products\n6. Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, and sleep) as much as possible throughout the study\n7. Provided voluntary, written, informed consent to participate in the study\n8. Agrees to have de-identified photos of face available for marketing purposes\n9. Self-reported healthy as determined by medical history with no unstable diagnosed medical conditions\n\nExclusion Criteria:\n\n1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study\n2. Self-reported allergy, sensitivity or intolerance to investigational product or placebo ingredients, including allergy to salicylic acid or any form of salicylates, preventing topical use\n3. Individuals with significant facial hair that would impede the visualization of facial acne and may interfere with the use of the product, such as beards and long sideburns, as assessed by the QI\n4. Self-reported psoriasis, dermatitis, vitiligo, or any other active dermatological condition other than acne affecting the face\n5. Self-reported use of topical products on the face marked with claims relating to skin health, or those with claims relating to acne during the study, except for noncomedogenic moisturizers and sunscreen\n6. Self-reported shaving, waxing, tweezing, or threading of the face or use of nose\u002Ffacial strips within 3 days prior to each photo capture\n7. Procedures such as microdermabrasion, peels, acne treatments, filler, botulinum toxin, red light therapy, pore suction therapy, or laser on the face within three months of baseline\n8. Self-reported UVA or UVB exposure to the face in the past two weeks or expected during the study to avoid sunburn.\n9. Current use of prescribed and\u002For over-the-counter (OTC) medications, supplements, and\u002For consumption of food\u002Fdrinks that may impact the efficacy and\u002For safety of the investigational product (Sections 7.3.1 and 7.3.2)\n10. Self-reported asthma\n11. Self-reported presence of a peptic ulcer\n12. Self-reported autoimmune disease or are immune compromised\n13. Self-reported ongoing and unstable diseases\u002Fconditions in the past three months, including:\n\n    1. Arthritis and joint diseases\n    2. Gastrointestinal diseases\n    3. Hypertension\n    4. Type I or type II diabetes\n    5. Cardiovascular disease\n    6. Kidney diseases\n    7. Liver diseases\n    8. Thyroid condition\n    9. Psychiatric conditions\n14. Major surgery in the past 3 months or individuals who have planned surgery during the course of the study\n15. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable\n16. Alcohol intake average of \\>2 standard drinks per day\n17. Alcohol or drug abuse within the last 12 months\n18. Participation in other clinical research studies 30 days prior to screening\n19. Individuals who are unable to give informed consent\n20. Any other condition or lifestyle factor that may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant","18 Years","65 Years",{"count":66,"type":19},150,[22],"The goal of this interventional clinical trial is to investigate the efficacy and safety of GenLabs' Social Renew on improving acne symptoms and skin repair among healthy adults. The main question\\[s\\] it aims to answer is:\n\nWhat is the difference in the change in acne symptoms as assessed by the Acne Quality of Life Questionnaire (ACNE-QoL) between GenLabs' Social Renew and placebo from baseline at Day 30.",[29],[71,72,73],"GenLabs","Acne symptoms","Social Renew","2026-06-26",{"date":76,"type":48},"2026-06-30",{"date":78,"type":19},"2026-07",{"date":50,"type":19},{"name":81,"class":82},"GenCanna Acquisition Corp","INDUSTRY",1,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":91,"sex":15,"minAge":63,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":20,"phases":95,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":109},"100592162","phase-1-phase-1-study-to-evaluate-the-safety-tolerability-pk-and-pd-of-tvb-3567-in-healthy-participants-with-or-without-acne-100592162","NCT06989840","Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne","A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TVB-3567 in Healthy Participants With or Without Acne and to Assess the Effect of Food in Healthy Participants","Inclusion Criteria:\n\nHealthy Participants (Parts A, B and C)\n\n1. Healthy, adult, male or female 18-55 years of age\n2. Body mass index (BMI) ≥18.0 and ≤32.0 kg\u002Fm2\n3. Medically healthy with no clinically significant medical history\n4. Understands the study procedures in the informed consent form (ICF) and willing and able to comply with the protocol\n\nHealthy Participants with Acne (Part D only)\n\nParticipants must meet all of the above criteria, as well as the following inclusion criteria to be eligible for participation in the study:\n\n1. BMI ≥18.0 and ≤37.0 kg\u002Fm2.\n2. Must be diagnosed with moderate to severe acne vulgaris\n\nExclusion Criteria:\n\nHealthy Participants (Parts A, B and C)\n\n1. History or presence of clinically significant medical or psychiatric condition or disease\n2. History or presence of hypersensitivity or idiosyncratic reaction to the study drug or related compounds including over the counter acne products.\n3. Has a clinically significant ophthalmic examination finding\n4. Female participant of childbearing potential\n5. Unable to refrain from or anticipates the use of:\n\n   * Any drugs, including prescription and non-prescription medications, herbal remedies, or vitamin supplements\n   * Any topical anti-acne treatment on the face\n   * Any drugs known to be moderate or strong inducers of CYP3A4 enzymes, BCRP, and\u002For P gp, including St. John's Wort, beginning 28 days prior to the first dosing.\n   * Part C only: Any previous tretinoin treatments, including tazarotene, adapalene, isotretinoin, and all-trans retinoic acid.\n\nHealthy Participants with Acne (Part D only)\n\nParticipants must not be enrolled if they do not meet any of the above criteria, as well as the following exclusion criteria:\n\n1. Unable to refrain from or anticipates the use of:\n\n   * Any previous tretinoin treatments, including tazarotene, adapalene, isotretinoin, and all trans retinoic acid.\n   * Photoelectric therapy, dermabrasion, or chemical peeling\n   * Intra-articular and systemic corticosteroid therapy\n2. Significant skin diseases",true,"55 Years",{"count":94,"type":19},128,[96],"PHASE1","This is a 4-part study. Part A will be a randomized, double-blind, placebo-controlled investigation of single ascending doses (SAD) to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) biomarkers of TVB-3567 administered orally in healthy participants. Part B will be a randomized, open-label, 2-way crossover investigation to assess the effect of food on a single dose TVB-3567 administered orally in healthy participants. Parts C and D will be randomized, double-blind, placebo-controlled investigations of multiple ascending doses (MAD) to assess the safety, tolerability, PK, and PD\u002Fbiomarkers of TVB-3567 administered orally in healthy participants without and with moderate to severe acne, respectively.",[29],"RECRUITING","2026-06-07",{"date":102,"type":48},"2026-06-09",{"date":104,"type":48},"2025-06-03",{"date":106,"type":19},"2027-01",{"name":108,"class":82},"Sagimet Biosciences Inc.",2,{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":15,"minAge":63,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":20,"phases":120,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":4},"100592340","early-phase-1-role-of-akkermansia-muciniphila-in-acne-vulgaris-100592340","NCT06992154","Role of Akkermansia Muciniphila in Acne Vulgaris","Acne Treatment With Akkermansia Muciniphila, Clostridium Beijerinckii, Anaerobutyricum Hallii, Clostridium Butyricum, Bifidobacterium Infantis Probiotic Capsule to Impact Metabolic Health","Inclusion Criteria:\n\n* Participants aged 18 to 45 years.\n* Individuals with clinically diagnosed moderate to severe acne vulgaris, determined using standardized scales like the Global Acne Grading\n* System (GAGS) by Investigators of the study.\n* Willingness to provide informed consent and adhere to study protocols, including follow-ups and sample collections.\n\nExclusion Criteria:\n\n* Recent and\u002For current antibiotic use: Individuals who have used antibiotics or probiotics within the last three months, as these can alter gut microbiota composition\n* Chronic gastrointestinal conditions: Participants with chronic gastrointestinal conditions such as Chron's disease, ulcerative colitis or irritable bowel syndrome (IBS).\n* Immune disorders: Individuals with known immune deficiencies or autoimmune diseases, which might affect inflammation levels and study outcomes.\n* Pregnancy or Lactation: pregnant or breastfeeding women, due to potential risk and hormonal changes that could influence acne and gut health.\n* Inability or unwillingness of subject or legal guardian\u002Frepresentative to give informed consent\n* Oral acne medications, including isotretinoin and spironolactone: these medications can significantly alter acne severity, making it difficult to isolate and accurately measure the effects of the probiotic intervention. Isotretinoin, a powerful retinoid, and spironolactone, a hormone-modulating medication, both have well-documented impacts on acne that could confound the study's results. Excluding participants using these medications ensures that changes in acne severity can be more directly attributed to the probiotic being tested, leading to clearer, more reliable findings on its efficacy.\n* History of metabolic disorders such as type 1 diabetes (DM1) and type 2 diabetes (DM2): DM1 and DM2 and their therapies can significantly alter baseline metabolic markers, such as glucose levels, insulin sensitivity, and inflammatory responses. Including such individuals might confound the results and make it difficult to attribute observed effects solely to the probiotics.\n* Chronic gastrointestinal conditions: Participants with chronic gastrointestinal conditions such as Crohn's disease, ulcerative colitis or irritable bowel syndrome (IBS).\n* Known hypersensitivity to \\>4 first-line antimicrobial therapies against Akkermansia muciniphila, Clostridium beijerinckii, Clostridium butyricum, Anaerobutyricum hallii: Penicillin, Piperacillin, Tetracycline, Amoxicillin, Ampicillin\n* Known hypersensitivity to \\>4 first-line antimicrobial therapies against Bifidobacterium infantis Bi-26TM: Gentamicin, Kanamycin, Streptomycin, Tetracycline, Erythromycin, Clindamycin, Ampicillin, Vancomycin\n* Known allergy or hypersensitivity to any of the following ingredients: Akkermansia muciniphila, Anaerobutyricum hallii, Bifidobacterium infantis, Clostridium beijerinckii, and Clostridium butyricum Other Ingredients: Chicory inulin and oligofructose (prebiotic fiber), hypromellose (vegetarian capsule), fruit \\& vegetable juice (coloring agent), magnesium stearate (flow agent for encapsulation), and silica.\n* Immune disorders: Individuals with known immune deficiencies or autoimmune diseases, which might affect inflammation levels and study outcomes.\n* BMI of greater than or equal to 45: Excess adiposity is likely to impact sex hormones, inflammation, insulin resistance, and GLP-1 levels. These factors could confound the study outcomes. Additionally, excess adiposity is associated with hyperandrogenism and changes in sex hormone-binding globulin (SHBG), which may independently influence acne severity and skew results.","45 Years",{"count":119,"type":19},34,[121],"EARLY_PHASE1","The project explores the use of Pendulum's Glucose Control, which contains a unique combination of probiotics, including Akkermansia muciniphila, Clostridium beijerinckii, Anaerobutyricum hallii, Clostridium butyricum, and Bifidobacterium infantis, to treat acne by improving gut health and reducing inflammation. These probiotic strains work synergistically to enhance the gut's protective barrier, lower harmful substances such as lipopolysaccharides, and increase the production of beneficial compounds like short-chain fatty acids, which can help modulate immune response and inflammation associated with acne. By integrating this probiotic combination into treatment strategies, the approach aims to offer a natural and effective solution for clearer skin. Additionally, the project seeks to investigate the correlation between postprandial glucose spikes and acne flare-ups. Continuous glucose monitoring (CGM) will be employed to track blood glucose fluctuations following meals, providing valuable insights into the potential link between metabolic responses and acne severity. This comprehensive approach aims to enhance understanding of how gut health, inflammation, and metabolic factors interact in the context of acne management.",[29],"2026-05-11",{"date":126,"type":48},"2026-05-12",{"date":128,"type":19},"2027-03",{"date":130,"type":19},"2029-01",{"name":132,"class":55},"Medical University of South Carolina",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":141,"minAge":142,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":20,"phases":146,"briefSummary":147,"conditions":148,"keywords":155,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":83},"100619166","skin-inflammation-in-perimenopause-a-probiotic-intervention-proof-of-concept-trial-100619166","NCT07341087","Skin Inflammation in (Peri)Menopause: A Probiotic Intervention Proof of Concept Trial","Skin Inflammation in (Peri)Menopause: A Probiotic Intervention Proof of Concept Trial (SIPPI)","SIPPI","Inclusion Criteria:\n\n1. Female, aged 40-60 years.\n2. Self-reported or clinician-diagnosed non-infectious, non-autoimmune inflammatory skin condition affecting the face (e.g., rosacea, acne, eczema).\n3. Willing and able to consume a daily oral intervention (2x 65 ml probiotic drinks or skimmed milk) for 8 weeks.\n4. Willing and able to provide sufficient blood, skin and stool samples at baseline and end-of-study (Week 8). Participants unable to provide adequate blood sample volumes will not be able to start the intervention.\n5. Willing and able to provide a photograph of the facial area, with all images anonymised for study purposes.\n6. Able to comply with study procedures, including attending clinic visits at KCL.\n7. Have access to a refrigerator at home and be able to store the study product(s) safely after collection (i.e., travel time allows safe storage).\n8. Capable of providing written informed consent.\n9. Have sufficient proficiency in English to complete study questionnaires and assessments.\n\nExclusion Criteria:\n\n1. Inability or unwillingness to provide informed consent.\n2. Inability or unwillingness to comply with study protocol requirements (e.g., clinic visits, sample provision, daily consumption of study drink)\n3. Unwilling to record dietary intakes using handwritten diet diaries\n4. Not fluent in the English language\n5. Is planning on international travel during the study period\n6. Current participation in another interventional clinical trial or having received an investigational\u002Fpharmaceutical product within the past 3 months.\n7. Known allergy or intolerance to dairy products, skimmed milk, or probiotic drinks containing Lactobacillus species.\n8. Currently pregnant, currently breastfeeding or planning to become pregnant in the next 4 months.\n9. BMI \\\u003C18.5kg\u002Fm2 or \\> 35kg\u002Fm2.\n10. Unintentional weight loss greater than 4 kg in the 3 months prior to enrolment.\n11. History of substance abuse or alcoholism (alcohol intake \\>50 units\u002Fweek) within the last 12 months.\n12. Current smokers, or individuals who quit smoking in the last 6-months.\n13. Fasting glucose \\>7mmol\u002Fl (finger prick test at baseline clinic).\n14. Active skin infection requiring systemic antibiotics, antivirals, or antifungals within the past 4 weeks.\n15. Major gastrointestinal disease (e.g., inflammatory bowel disease, celiac disease, short bowel syndrome) or history of significant gastrointestinal surgery (excluding appendectomy or cholecystectomy).\n16. Known immunodeficiency (e.g., HIV, immunosuppressive therapy, systemic corticosteroids \\>10 mg\u002Fday prednisolone equivalent).\n17. History of malignancy or clinically significant non-malignant skin conditions within the past 5 years (except adequately treated basal cell carcinoma).\n18. Serious medical conditions that, in the opinion of the investigator, would compromise safety or interfere with study outcomes (e.g., uncontrolled diabetes, advanced cardiovascular, hepatic, or renal disease, active cancer, autoimmune conditions).\n19. Women with a history of severe psychiatric illness that would limit adherence to study requirements.\n20. Current use of probiotics, prebiotics, or antibiotics within 4 weeks prior to baseline.\n21. Current use of systemic corticosteroids, or other immunosuppressive\u002Fimmunomodulatory therapies within the past 3 months.\n22. Currently receiving, or having received, phototherapy (e.g., UVB, PUVA, laser\u002Flight-based treatments, including at home treatments) for any skin condition within the past 3 months.\n23. Currently receiving, or having received, systemic dermatology treatments likely to affect skin inflammation or immune response within the past 3 months (e.g., isotretinoin, methotrexate, cyclosporine, biologics such as TNF, IL-17, IL-23 or IL-4\u002FIL-13 inhibitors).\n24. Currently receiving, or having received, topical treatments likely to significantly alter skin inflammation within the past 3 months (e.g., high-potency topical corticosteroids, topical calcineurin inhibitors such as tacrolimus or pimecrolimus, topical retinoids, or photodynamic therapy).\n25. Currently using, or have used, probiotic skincare (e.g., topical creams and serums) within the past 3 months.\n26. Currently receiving, have undergone, or plan to undergo cosmetic skin procedures (e.g., chemical peels, laser therapy, dermal fillers, microneedling) within the 3 months prior to, or within 3 months after the first (baseline) visit.\n27. Currently using, or have used, hormonal contraceptives or treatments known to exacerbate skin conditions, including Mirena (levonorgestrel-releasing intrauterine system), oral progesterone-only contraceptives (e.g., mini-pill), and synthetic progestogens (e.g., norethisterone) within the past 3 months.","FEMALE","40 Years","60 Years",{"count":145,"type":19},30,[22],"This study will explore whether a daily probiotic drink containing Lactobacillus casei Shirota (LcS) can help improve immune function and reduce inflammation in women going through the menopausal transition. Hormonal changes during this stage of life can affect the immune system, gut health, and skin, sometimes leading to increased inflammation or conditions such as eczema, acne or rosacea.\n\nParticipants will consume either a low-sugar LcS probiotic drink or a skimmed milk control drink every day for eight weeks. The study will assess markers of immune ageing, inflammation, skin health, wellbeing, and hormone levels. The results will help determine whether a safe, non-hormonal probiotic approach may support immune and skin health during the menopausal transition.",[149,150,151,152,26,153,29,154],"Skin Inflammation","Immunosenescence","Inflammation","Skin Health","Rosacea","Menopause",[156,157,158,159,160,161],"Probiotics","Lactobacillus casei Shirota","Immune ageing","Gut-skin axis","Skin health","Menopausal transition","2026-05-05",{"date":164,"type":48},"2026-05-08",{"date":166,"type":48},"2026-04-28",{"date":168,"type":19},"2027-11-01",{"name":170,"class":55},"King's College London",{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":15,"minAge":63,"maxAge":117,"enrollmentInfo":178,"targetDuration":4,"studyType":20,"phases":180,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":192},"100540396","phase-1-study-to-evaluate-safety-efficacy-and-immunogenicity-of-acne-mrna-vaccine-in-adults-with-moderate-to-severe-acne-100540396","NCT06316297","Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne","A Phase I\u002FII, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age","Inclusion Criteria:\n\n* Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, and laboratory tests as judged by the investigator\n* Clinical diagnosis of moderate or severe facial acne vulgaris with Investigator's Global Assessment (IGA) score of Moderate or Severe (grade 3 or grade 4 on the 5-grade IGA scale) and ≥ 25 non-inflammatory lesions (ie, open and closed comedones) and ≥ 20 inflammatory lesions (ie, papules and pustules) and ≤ 2 nodulocystic lesions (ie, nodules and cysts)\n\nExclusion Criteria:\n\nParticipants are excluded from the study if any of the following criteria apply:\n\n* Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within 6 months prior to the first study intervention administration; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)\n* Known systemic hypersensitivity to any of the study intervention components; history of a life-threatening reaction to the study interventions used in the study or to a product containing any of the same substances; any allergic reaction (eg, anaphylaxis) after administration of mRNA coronavirus disease 2019 (COVID-19) vaccine\n* Active nodulocystic acne, acne conglobate, acne fulminans, secondary acne (eg, chloracne, drug-induced acne) or other forms of acne (eg, acne mechanica)\n* Use of any acne-affecting treatment without an appropriate washout period\n* Receipt of any vaccine (other than the study vaccine) in the 4 weeks preceding any study intervention administration or planned receipt of any vaccine (other than the study vaccine) in the 4 weeks following any study intervention administration\n* Previous vaccination against C. acnes with an investigational vaccine\n* Receipt of immune globulins, blood or blood-derived products in the past 3 months\n* Self-reported or documented seropositivity for human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus.\n\nThe above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.",{"count":179,"type":19},800,[96,181],"PHASE2","The purpose of the trial is to evaluate the safety, efficacy and immunogenicity of up to 3 intramuscular injections of the Acne mRNA vaccine candidate at up to four dose levels in adult participants aged 18 to 45 years with moderate to severe acne.\n\nThis trial will consist of a Core Study followed by an optional Long-Term Extension (LTE).\n\nThe Core Study will consist of:\n\n* Two cohorts evaluating the 2-administration regimen (Cohorts A): Sentinel Cohort A and Main Cohort A.\n* Two cohorts evaluating the 3-administration regimen (Cohorts B): Sentinel Cohort B and Main Cohort B.\n\nParticipants from Sentinel Cohorts A and B and from Main Cohort A will be invited to an additional 30-month follow up after completing their last planned Core Study visit to assess the long-term effects of the vaccine. Participants from Main Cohort B will be invited to another LTE study managed through a separate protocol.",[29],"2026-04-30",{"date":162,"type":48},{"date":187,"type":48},"2024-04-05",{"date":189,"type":19},"2028-11-30",{"name":191,"class":82},"Sanofi Pasteur, a Sanofi Company",93,{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":20,"phases":202,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":4},"100599813","photodynamic-therapy-with-topical-application-of-a-znii-phthalocyanine-rlp068cl-and-red-light-for-the-treatment-of-moderate-to-severe-acne-vulgaris-100599813","NCT07089368","Photodynamic Therapy With Topical Application of a Zn(II) Phthalocyanine (RLP068\u002FCl) and Red Light for the Treatment of Moderate-to-severe Acne Vulgaris","PHOTAC","Inclusion Criteria:\n\n* Male or female participants aged ≥16 years.\n* Diagnosis of moderate-to-severe acne vulgaris (comedonal, papulopustular, or cystic), with facial lesions symmetrically distributed.\n* Washout period of at least 6 months from prior oral acne treatments.\n* Washout period of at least 2 months from prior topical acne treatments.\n* Ability to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Use of systemic or topical photosensitizing medications.\n* Known photosensitivity disorders.\n* Pregnancy or breastfeeding.\n* Participation in another interventional clinical study within the past 3 months.\n* Any dermatological condition of the face that may interfere with treatment assessment (e.g., eczema, rosacea).\n* Any serious uncontrolled medical condition deemed by the investigator to pose a risk to the participant or interfere with study results.",{"count":201,"type":19},10,[22],"This pilot clinical study will evaluate the safety, tolerability, and effectiveness of a novel photodynamic therapy (PDT) for moderate-to-severe acne vulgaris. PDT combines a topical photosensitizing gel with red light to treat acne lesions. The gel to be used in this study, called RLP068\u002FCl (a zinc phthalocyanine compound), has demonstrated antimicrobial, anti-inflammatory, and sebosuppressive effects in laboratory studies.\n\nA total of 10 patients with moderate-to-severe acne on the face will be enrolled. RLP068\u002FCl 0.3% gel will be applied topically for 30 minutes under occlusion, followed by 8 minutes of red LED light exposure. Treatments will be performed twice weekly, with the total number of sessions individualized based on clinical response.\n\nAcne severity will be assessed using the Global Acne Grading System (GAGS). Pain levels will be recorded after each session using a visual scale, and patient satisfaction will be evaluated at the end of the treatment cycle.\n\nThe goal of the study is to determine whether RLP068\u002FCl-PDT is a safe, well-tolerated, and effective non-antibiotic treatment option for patients with moderate-to-severe acne vulgaris who may not respond to or tolerate conventional therapies.",[29],{"date":206,"type":48},"2026-05-04",{"date":208,"type":19},"2026-08",{"date":210,"type":19},"2027-04",{"name":212,"class":55},"Università degli Studi di Brescia",{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":91,"sex":15,"minAge":220,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":20,"phases":223,"briefSummary":224,"conditions":225,"keywords":229,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":4},"100635218","sebum-metabolomics-and-lipidomics-for-clinical-applications-100635218","NCT07549828","Sebum Metabolomics and Lipidomics for Clinical Applications","Development of a Sample Collection Protocol and a Metabolomics\u002FLipidomics Analytical Strategy for Investigating Sebum and Its Clinical Applications","A. Healthy Participants\n\nInclusion Criteria:\n\n* Individuals aged ≥20 years, regardless of sex or ethnicity, and assessed by the investigator to be in good health and suitable for participation.\n* No diagnosed skin diseases or chronic systemic diseases.\n* No use of medications or receipt of dermatological treatments that may affect sebum secretion or the skin microbiome within the past two weeks.\n\nExclusion Criteria:\n\n* Known allergy to Sebutape or similar adhesive tapes, or a history of related adverse reactions.\n* Presence of acute or chronic skin diseases, or chronic systemic diseases.\n* Use of medications or receipt of dermatological treatments that may affect sebum secretion or the skin microbiome within the past two weeks.\n* Use of lotions, sunscreen, or other skincare products that may affect skin condition within 12 hours prior to sampling.\n* Any other conditions deemed unsuitable for participation by the principal investigator.\n\nB. Participants with Skin Diseases or Specific Skin Conditions\n\nInclusion Criteria:\n\n* Individuals aged ≥20 years, regardless of sex or ethnicity, and assessed by the investigator to be suitable for participation.\n* Diagnosed by a physician or clinically assessed as having one of the following:\n\n  * Acne\n  * Atopic dermatitis\n  * Seborrheic dermatitis\n  * Psoriasis\n  * Other common skin diseases\n  * Specific skin conditions (e.g., postmenopausal or aging-related skin changes)\n\nExclusion Criteria:\n\n* Known allergy to Sebutape or similar adhesive tapes, or a history of related adverse reactions.\n* Severe disease that may compromise skin integrity or pose a risk to participant safety.\n* Use of lotions, sunscreen, or other skincare products that may affect skin condition within 12 hours prior to sampling.\n* Any other conditions deemed unsuitable for participation by the principal investigator.\n\nC. Participants Receiving Dermatological Treatments or Using Skincare Products\n\nInclusion Criteria:\n\n* Individuals aged ≥20 years, regardless of sex or ethnicity, and assessed by the investigator to be suitable for participation.\n* Participants who, based on clinical needs or daily routines, are currently using or are expected to use or receive any of the following:\n\n  * Physician-prescribed topical dermatological medications\n  * Physician-prescribed systemic therapies (oral or injectable)\n  * Routine use of general skincare products\n  * Physician-directed non-invasive dermatological treatments\n\nExclusion Criteria:\n\n* Known allergy to Sebutape or similar adhesive tapes, or a history of related adverse reactions.\n* Severe disease that may compromise skin integrity or pose a risk to participant safety.\n* Use of lotions, sunscreen, or other skincare products that may affect skin condition within 12 hours prior to sampling.\n* Any other conditions deemed unsuitable for participation by the principal investigator.\n\nD. Healthy Participants Undergoing Short-term Antibiotic Intervention\n\nInclusion Criteria:\n\n* Individuals aged ≥20 years, regardless of sex or ethnicity.\n* Assessed by the investigator to be healthy, with skin condition suitable for the intervention used in this study.\n\nExclusion Criteria:\n\n* Known allergy to Sebutape or similar adhesive tapes, or a history of related adverse reactions.\n* Known allergy or adverse reactions to the study intervention drug (topical antibiotic ointment containing bacitracin, polymyxin B, and neomycin).\n* Presence of visible skin disease, wounds, infection, inflammation, or other abnormal skin conditions at the sampling site.\n* Use of lotions, sunscreen, or other skincare products that may affect skin condition within 12 hours prior to sampling.\n* Any other conditions deemed unsuitable for participation by the principal investigator.","20 Years",{"count":222,"type":19},200,[22],"This study aims to develop a standardized workflow for sebum sampling and metabolomics\u002Flipidomics analysis using Sebutape. A total of 200 participants will be recruited, including healthy individuals, patients with skin diseases, individuals undergoing dermatological treatments or using skincare products, and a subset of healthy participants receiving short-term topical antibiotic intervention. The study will investigate sebum composition, skin microbiome profiles, and their interactions under different conditions to explore potential biomarkers and clinical applications.",[29,226,227,28,228],"Atopic Dermatitis","Seborrheic Dermatitis","Healthy Subjects (HS)",[230,231,232,233,234,235],"Sebum","Lipidomics","Metabolomics","Skin microbiome","Sebutape","LC-MS\u002FMS","2026-04-17",{"date":238,"type":48},"2026-04-24",{"date":240,"type":19},"2026-04-01",{"date":242,"type":19},"2029-03-31",{"name":244,"class":55},"National Taiwan University Hospital",{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":251,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":253,"targetDuration":254,"studyType":255,"phases":4,"briefSummary":256,"conditions":257,"keywords":258,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":83},"100321460","creation-of-a-monocentric-cohort-of-patients-treated-for-acne-at-the-nantes-university-hospital-100321460","NCT03465150","Creation of a Monocentric Cohort of Patients Treated for Acne at the Nantes University Hospital","Creation of a Monocentric Cohort of Patients Treated for Acne at the Nantes University Hospital: the COPACNE Cohort.","COPACNE","Inclusion Criteria:\n\n* Patient with acne\n* Patient (or parents\u002Fguardians for minors) who are not opposed to participating in the cohort.\n* Subjects affiliated to an appropriate health insurance\n\nExclusion Criteria:\n\n* Dermatosis of the face other than acne\n* Refusal to participate by the minor or parent\u002Fguardian\n* Adults under a legal protection regime (guardianship, trusteeship, judicial safeguard)",{"count":222,"type":19},"2 Years","OBSERVATIONAL","With 24 million results associated with Google's searchon keywords \"severe acne\", Pr Dreno's team understand better thatthis disease, which affects many French people, is a real concern of Public Health and not a \"forced evil\" of the adolescent period, which will eventually resolve itself. Acne does not affect the vital prognosis, but its psychosocial impact is major and should not be underestimated. Paradoxically, despite the high prevalence of acne, few quality epidemiological studies have been published. Physicians are often helpless when faced with patients' questions. They often need a lot of explanations, especially on the factors aggravating this dermatosis, which greatly affects their quality of life.\n\nThis cohort, the first of its kind in France, will determine the predictive factors of therapeutic response, endogenous and environmental factors impacting on the severity of acne assess the quality of life and psychological impact of acne patients, determine the patient's course of care and the associated costs. Pr Dreno's team will also build up a bio collection (bacteriological samples).",[29],[29,259,260,261],"Cohort","prospective","risk factors","2026-04-07",{"date":264,"type":48},"2026-04-13",{"date":266,"type":48},"2018-09-23",{"date":268,"type":19},"2033-12-28",{"name":270,"class":55},"Nantes University Hospital",{"id":272,"slug":273,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":11,"sex":15,"minAge":63,"maxAge":278,"enrollmentInfo":279,"targetDuration":4,"studyType":20,"phases":281,"briefSummary":282,"conditions":283,"keywords":284,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":293,"locationsCount":83},"100621100","phase-2-topical-application-of-engineered-lactobacillus-reuteri-with-a-zinc-sulfate-tannic-acid-mpn-coating-for-acne-100621100","NCT07366229","Topical Application of Engineered Lactobacillus Reuteri With a Zinc Sulfate-Tannic Acid MPN Coating for Acne","Evaluating Engineered Lactobacillus Reuteri With a Zinc Sulfate-Tannic Acid MPN Coating for Acne: A Double-Blind, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Subjects must be diagnosed with acne (based on history, clinical manifestation, and dermatoscopy) and classified as Grade I to III per the International Improved Grading System.\n2. Subjects must be willing and able to provide written informed consent.\n3. Subjects must be 18 to 33 years of age and in generally good health.\n4. Subjects must have more than 9 inflammatory lesions.\n\nExclusion Criteria:\n\n1. Have used antibiotics within 1 month before the study start.\n2. Have used systemic retinoid therapy within 3 months before the study start.\n3. Have undergone any other acne treatment within 1 month before the study start.\n4. Have any other condition that the investigator considers would make participation unsuitable (e.g., deemed unreliable, non-compliant, or unable to comprehend the study assessments).","33 Years",{"count":280,"type":19},196,[181],"A growing body of evidence suggests that the development and progression of acne are closely linked to an imbalance in the skin's microbial community. Compared to healthy skin, the composition and function of the microbiota in acne lesions are significantly altered. This microbial imbalance is believed to drive the formation and recurrence of acne through mechanisms such as triggering abnormal inflammatory responses and compromising the skin barrier.\n\nAn in-depth exploration of the interaction between acne and the skin microbiome not only offers new perspectives for understanding the root causes of the disease but also lays the groundwork for developing novel treatment strategies aimed at modulating the microbiota. Therefore, identifying innovative approaches that integrate acne treatment with the regulation of microbial balance holds significant clinical and social value.\n\nAlthough existing acne treatments have made progress, research focusing on interventions that regulate the local skin microecology through probiotics remains relatively limited. This study aims to explore a new strategy based on skin microecological modulation. Investigators are using a common probiotic-Lactobacillus reuteri-and applying an engineering modification with a special coating formed by zinc sulfate and tannic acid (MPN coating). This modification is intended to enhance the bacterium's survival and colonization on the skin, thereby more effectively regulating the local microbiota and reducing inflammation.\n\nThis study is a rigorous scientific clinical trial designed as randomized, double-blind, and controlled. Eligible participants will be randomly assigned to one of four groups, receiving either the engineered Lactobacillus reuteri cream, the plain Lactobacillus reuteri cream, a simple moisturizing cream (placebo), or an already-marketed effective cream (tretinoin cream). The treatment will last for 2 weeks, followed by an 8-week observation period. Efficacy and safety will be evaluated through professional assessments.\n\nOur goal is to scientifically evaluate the safety and efficacy of this new therapy, hoping to provide a potential new treatment option for individuals with acne and explore new pathways for improving skin health.",[29],[285,286],"acne","Lactobacillus reuteri","2026-03-31",{"date":289,"type":48},"2026-04-06",{"date":291,"type":48},"2025-12-30",{"date":76,"type":19},{"name":294,"class":55},"Shenzhen People's Hospital",{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":91,"sex":15,"minAge":63,"maxAge":4,"enrollmentInfo":302,"targetDuration":4,"studyType":255,"phases":4,"briefSummary":304,"conditions":305,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":83},"100515705","collection-of-samples-from-subjects-with-various-skin-conditions-and-healthy-volunteers-100515705","NCT05994976","Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers","Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers for Molecular Characterization of Inflammatory Skin Diseases","Inclusion Criteria:\n\nAll subjects:\n\n1. Subject is willing to participate and is capable of giving informed consent. Note: Consent must be obtained prior to any study-related procedures.\n2. Subject must be willing to comply with all study procedures and must be available for the duration of the study.\n\n   Healthy volunteers:\n3. Male or female subject aged 18 years or older, at the time of consent.\n4. Subject is in good general health, according to the investigator's judgment.\n\n   Subjects with Acne:\n5. Male or female subject aged 18 to 45 years old, inclusive, at the time of consent.\n\n   Subjects with AD:\n6. Male or female subject aged 18 years or older, at the time of consent.\n7. Subject has clinically confirmed diagnosis of active AD, according to Hanifin and Rajka criteria.\n\n   Subjects with CHE:\n8. Male or female subject aged 18 years or older, at the time of consent.\n9. Subject has at least a 6-month history of CHE before Screening (information obtained from medical chart or subject's physician, or directly from the subject).\n\n   Subjects with HS:\n10. Male or female subject aged 18 years or older, at the time of consent.\n11. Subject has a clinically confirmed diagnosis of active HS with a disease duration of ≥ 6 months before screening as determined by the investigator through subject interview and\u002For review of the medical history.\n\n    Subjects with PPP:\n12. Male or female subject aged 18 years or older at the time of consent.\n13. Subject has at least a 6-month history of PPP as defined by the presence of pustules on palms and\u002For soles, but without evidence of infection on palms and soles (information obtained from medical chart or subject's physician, or directly from the subject).\n\n    Subjects with psoriasis:\n14. Male or female subject aged 18 years or older, at the time of consent.\n\nExclusion Criteria:\n\nAll subjects:\n\n1. Subject is a female who is pregnant or who is planning to become pregnant during the study.\n2. Subject has a history of skin disease or presence of skin condition that, in the opinion of the investigator, would interfere with the study assessments.",{"count":303,"type":19},500,"The purpose of the study is to collect different samples for molecular characterization of inflammatory skin diseases.",[29,226,306,307,308,309],"Chronic Hand Eczema","Hidradenitis Suppurativa","Plaque Psoriasis","Palmoplantar Pustulosis","2026-03-25",{"date":312,"type":48},"2026-03-30",{"date":314,"type":48},"2023-10-17",{"date":316,"type":19},"2028-08",{"name":318,"class":55},"Innovaderm Research Inc.",{"id":320,"slug":321,"hasResults":11,"nctId":322,"briefTitle":323,"officialTitle":323,"acronym":324,"eligibilityCriteria":325,"healthyVolunteers":91,"sex":15,"minAge":63,"maxAge":326,"enrollmentInfo":327,"targetDuration":328,"studyType":255,"phases":4,"briefSummary":329,"conditions":330,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":4},"100624592","non-interventional-translational-study-in-mild-moderate-and-severe-acne-patients-100624592","NCT07411638","Non-interventional Translational Study in Mild, Moderate and Severe Acne Patients","VBE00011","INCLUSION CRITERIA:\n\nAGE I01: Aged 18 to 25 years on the day of inclusion.\n\nTYPE OF PARTICIPANT AND DISEASE CHARACTERISTICS\n\nI02: Participants with a formal diagnosis of either:\n\n* Mild facial acne vulgaris defined as Investigator's Global Assessment (IGA) of 2, or\n* Moderate facial acne vulgaris defined as IGA score of 3, or\n* Severe facial acne vulgaris defined as IGA score of 4, or\n* Healthy volunteers without acne defined as IGA score of 0.\n\nINFORMED CONSENT I03: Informed consent form has been signed and dated by participant capable of providing informed consent.\n\nNote: For minor participants, informed consent form must also be signed and dated by the parent(s) or another legally acceptable representative(s).\n\nOTHER INCLUSIONS I04: Participant or participant and parent(s)\u002Flegally acceptable representative(s) are able to attend all scheduled visits and to comply with all study procedures.\n\nEXCLUSION CRITERIA\n\nParticipants are not eligible for the study if any of the following criteria are met:\n\nMEDICAL CONDITIONS E01: Thrombocytopenia, presence of bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating blood sampling, currently or previously suffering from any immune disorder.\n\nE02: Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion.\n\nE03: Active nodulocystic acne, acne conglobata, acne fulminans, secondary acne (eg, chloracne, drug-induced acne) or other forms of acne (eg, acne mechanica).\n\nE04: Skin pathology or condition that, in the investigator's opinion, could interfere with the evaluation of the study intervention or requires use of interfering topical, systemic, or surgical therapy.\n\nE05: Excessive facial hair, facial tattoos, facial skin disorders, skin reactions that may interfere with the study assessments in the investigator's opinion (including - but not limited to - actinic keratosis, eczema, psoriasis, seborrheic dermatitis, rosacea, acute or recent sunburn) or skin infection.\n\nE06: Alcohol, prescription drug, or substance abuse that, in the opinion of the investigator, might interfere with the study conduct or completion.\n\nE07: Self-reported or documented seropositivity for human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus.\n\nE08: Moderate or severe acute illness\u002Finfection (according to investigator judgment) or febrile illness (temperature ≥ 38.0°C \\[≥ 100.4°F\\]) on the day of samplings. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.\n\nPRIOR\u002FCONCOMITANT THERAPY:\n\nE09: Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within 6 months prior to the study sample collection; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks) within 3 months from study sample collection.\n\nE10: Start or switch of hormonal contraceptive use within 12 weeks prior to the study visit.\n\nE11: Previous use of oral isotretinoin. E12: Use of any acne-affecting treatment without an appropriate washout period (antibacterial\u002Fantifungal\u002Fantiseptic medications or topicals). Participants receiving prohibited medications\u002Ftherapies at Screening Visit will have to observe a washout period of 2 to 24 weeks before enrolment to preserve eligibility in the study.\n\nE13: Previous vaccination against C. acnes with an investigational vaccine E14: Receipt of immune globulins, blood or blood-derived products in the past 3 months E15: Pregnant or lactating women\n\nPRIOR\u002FCONCURRENT CLINICAL STUDY EXPERIENCE E16: Participation at the time of study enrolment or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure.\n\nOTHER EXCLUSIONS:\n\nE17: Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.\n\nE18 Identified as an Investigator or employee of the Investigator or study centre with direct involvement in the proposed study, or identified as an immediate family member (ie, parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.","25 Years",{"count":222,"type":19},"1 Day","This study aims to uncover the specific immunopathology, microbiome and pathophysiology of acne vulgaris in people living in a tropical climate such as Singapore. This is a largely unexplored population in terms of acne pathogenesis, and will lead to population-specific interventions for the management of acne vulgaris.",[29],"2026-02-06",{"date":333,"type":48},"2026-02-17",{"date":335,"type":19},"2026-02-15",{"date":337,"type":19},"2029-02-14",{"name":339,"class":340},"National Skin Centre","NETWORK",{"id":342,"slug":343,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":11,"sex":15,"minAge":63,"maxAge":117,"enrollmentInfo":348,"targetDuration":4,"studyType":20,"phases":350,"briefSummary":351,"conditions":352,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":361},"100594000","phase-1-study-to-evaluate-safety-efficacy-and-immunogenicity-of-acne-mrna-vaccine-in-participants-with-mild-acne-100594000","NCT07013747","Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne","A Phase 1\u002F2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Participants With Mild Acne","Inclusion Criteria:\n\n* Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, and laboratory tests as judged by the investigator\n* Clinical diagnosis of mild facial acne vulgaris with:\n\n  * IGA score of mild (grade 2 on the 5-grade IGA scale) AND\n  * between 10 to 24 non-inflammatory lesions (ie, open and closed comedones) AND\n  * between 5 to 19 inflammatory lesions (ie, papules and pustules) AND\n  * no nodulocystic lesions (ie, nodules and cysts)\n\nExclusion Criteria:\n\nParticipants are excluded from the study if any of the following criteria apply:\n\n* Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within 6 months prior to the first study intervention administration; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)\n* Known systemic hypersensitivity to any of the study intervention components (eg, polyethylene glycol \\[PEG\\], polysorbate); history of a life-threatening reaction to the study interventions used in the study or to a product containing any of the same substances; any allergic reaction (eg, anaphylaxis) after administration of mRNA coronavirus disease 2019 (COVID 19) vaccine\n* Previous history of myocarditis and\u002For pericarditis and\u002For myopericarditis\n* Skin pathology or condition that, in the investigator's opinion, could interfere with the evaluation of the study intervention or requires use of interfering topical, systemic, or surgical therapy\n* Excessive facial hair, facial tattoos, facial skin disorders, skin reactions that may interfere with the study assessments in the investigator's opinion (including - but not limited to - actinic keratosis, eczema, psoriasis, seborrheic dermatitis, rosacea, acute or recent sunburn) or skin infection\n* Receipt of immune globulins, blood or blood-derived products in the past 3 months\n* Self-reported or documented seropositivity for human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus",{"count":349,"type":19},120,[96,181],"The purpose of the VBE00009 study is to evaluate the safety, efficacy and immunogenicity of 2 administrations of the Acne mRNA vaccine candidate at single dose level in participants aged 18 to 45 years with mild acne. This study will consist of a Core Study followed by an optional Long-Term Extension (LTE). Core Study will include a Sentinel Cohort and a Main Cohort, with the Sentinel Cohort assessing the safety in a stepwise manner. If the participants consent to the LTE, they will be followed up for an additional 30 months after the last planned visit in the Core Study, to assess the long term effects of the vaccine.",[29],"2025-08-28",{"date":355,"type":48},"2025-09-05",{"date":357,"type":48},"2025-07-03",{"date":359,"type":19},"2029-06-19",{"name":191,"class":82},4,{"id":363,"slug":364,"hasResults":11,"nctId":365,"briefTitle":366,"officialTitle":366,"acronym":4,"eligibilityCriteria":367,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":368,"targetDuration":4,"studyType":255,"phases":4,"briefSummary":370,"conditions":371,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":109},"100581444","pmcf-investigation-of-medical-device-chitocare-medical-100581444","NCT06850389","PMCF Investigation of Medical Device ChitoCare® Medical","The inclusion criteria are fully according to indications:\n\n* Gel - scars, conditions after dermatosurgical procedures, dermatitis, acne\n* Spray - conditions after dermatosurgical procedures, dermatitis, acne\n\nThe criteria for exclusion are fully according to contraindications:\n\n* Allergy to any of the ingredients of the product",{"count":369,"type":19},214,"This is a post-marketing observational clinical investigation conducted as part of the post-market clinical follow-up of ChitoCare® Medical, aimed to confirm safety and efficacy according to the requirements of Regulation (EU) 2017\u002F745 of the European Parliament and of the Council of 5 April 2017 on medical devices, for the following indications:\n\nGel - scars, conditions after dermatosurgical procedures, dermatitis, acne\n\nSpray - conditions after dermatosurgical procedures, dermatitis, acne",[372,29,373,374],"Dermatitis","Conditions After Dematosurgical Procedures","Scars","2025-08-13",{"date":377,"type":48},"2025-08-17",{"date":379,"type":48},"2025-06-11",{"date":381,"type":19},"2025-12",{"name":383,"class":82},"Primex ehf",{"id":385,"slug":386,"hasResults":11,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":4,"eligibilityCriteria":390,"healthyVolunteers":11,"sex":15,"minAge":391,"maxAge":4,"enrollmentInfo":392,"targetDuration":4,"studyType":255,"phases":4,"briefSummary":394,"conditions":395,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":4},"100596328","an-observational-clinical-study-to-evaluate-the-efficacy-of-the-cerave-skin-care-line-100596328","NCT07044024","An Observational Clinical Study to Evaluate the Efficacy of the CeraVe Skin Care Line","An Observational Clinical Study to Evaluate the Efficacy of the CeraVe Skin Care Line in Improving Mild to Severe Acne on the Face","Inclusion Criteria:\n\n* Chinese males and females, age eligible greater than or equal to 13 years old;\n* Be in good health and free from any other chronic disease or disease under treatment;\n* Be judged by a dermatologist at the Baseline visit:\n\nMild, moderate, or severe acne according to the Global Evaluation Acne Grading Scale (GEA)11,12 (Mild - Grade 1 or Grade 2) Acne Grading Scale (GEA) - Scale 1 or 2, Moderate - Scale 3, Severe - Scale 4 or above);\n\n* Initiation of acne treatment within the last 3 months with medications that include, but are not limited to, the following\n\n  1. Topical medications: benzoyl peroxide (BPO), retinoic acid, adapalene, isotretinoin, azelaic acid, 0.1% adapalene\u002FBPO. b) Topical medications: benzoyl peroxide (BPO), retinoic acid, adapalene, isotretinoin, azelaic acid, adapalene 0.3% adapalene\u002FBPO, retinoic acid\u002Fclindamycin, BPO\u002Fclindamycin;\n  2. Oral medications: antibiotics, spironolactone, isotretinoin, etc; If Global Evaluation Acne Grading Scale (GEA) classification is ≥2, continuous use of the above medications for at least 2 weeks prior to the baseline visit is required.\n\n     If the Global Evaluation Acne Grading Scale (GEA) is ≥2, acne treatment with the above medications should be continued for at least 2 weeks before the baseline visit; If oral medication is used, acne treatment should be continued for at least 4 weeks prior to the baseline visit.\n\n     Exclusion Criteria:\n* Adult female study participants who intend to plan a pregnancy, or who are pregnant, breastfeeding, within 6 months of delivery, or who are unwilling to take the necessary precautions to avoid pregnancy;\n* Study participants who are currently enrolled in another clinical study or have been enrolled in another clinical study within 3 months;\n* Study participants who have undergone physical, chemical, or cosmetic surgery within 3 months prior to enrollment;\n* Systemic diseases with severe organ damage, cardiovascular diseases, liver or kidney dysfunction, malignant tumors, chronic diseases with unstable control, acute infectious diseases, major surgeries or traumas, psychological and psychiatric disorders, or other diseases that require topical or systemic use of medications or treatments that have an effect on acne;\n* The study site is associated with other skin disorders (atopic dermatitis, rosacea, rosacea, eczema, etc.) or the presence of other skin conditions that interfere with evaluation (birthmarks, scarring, etc.);\n* Participants in the study have a history of allergic contact dermatitis caused by cleansers (facial cleansers)\u002Fmoisturizers;\n* History of allergy or severe allergy to the products (Sensitive Skin products) and related ingredients provided in the study;\n* Study participants who are unable to follow compliance requirements, or who are known to be unable to attend visits on time, or who are unwilling to comply with the study protocol arrangements for the duration of the study;\n* Any clinical presentation or other illness in the required observation area that, in the opinion of the investigator, may affect the study product assessment or results.\n* Study participants had received medical aesthetic treatments (including but not limited to photofacial type treatments, fruit acid resurfacing, etc.) within 3 months prior to enrollment.","13 Years",{"count":393,"type":19},240,"This is an observational clinical study to evaluate the efficacy of the CeraVe Skin Care product line in improving mild to severe facial acne. Primary Objective: To evaluate the efficacy of CeraVe Skincare products in improving mild to severe facial acne through clinical observation by dermatologists of skin conditions before and after the use of the test product kit during the course of acne medication, as well as to collect concurrent feedback on the quality of life of this population and their experience with and satisfaction with the test product. Secondary objectives: 1. To collect feedback on the experience, satisfaction and quality of life improvement of CeraVe products through subjective evaluation of the subjects after using the products, in order to gain a deeper understanding of the comprehensive performance of the products in actual application; 2. To verify the tolerance of CeraVe products through clinical evaluation of the facial skin condition before and after the use of the products by dermatologists; 3. To evaluate the effectiveness of CeraVe products in improving acne. CeraVe is a dermatologist's clinical assessment of facial skin conditions before and after use to verify the tolerability and safety of CeraVe's skin care products. The study is designed to enroll approximately 240 male and female study participants aged 13 years or older with mild to severe facial acne, with a minimum sample size of 200 subjects based on a 15% dropout rate during the trial period and a protocol violation rate of no more than 5%. Participants entering the study will be classified as having mild, moderate, or severe acne according to the Global Evaluation Acne Grading Scale (GEA) (mild-grade 1 or grade 2, moderate-grade 3, severe-grade 4 or higher), with a sample size of mild acne:moderate acne:severe acne of approximately 1:1:1. The study was conducted over an 8-week period with 3 visits. They were conducted at the baseline visit (T0), week 4 follow-up (T4w) and week 8 follow-up (T8w). The window period was ±1 day for the week 4 (T4w) visit and ±2 days for the week 8 (T8w) visit. The primary evaluation parameters included: clinical assessment and product tolerance assessment by the dermatologist, patient self-assessment and questionnaires.",[29],"2025-06-23",{"date":398,"type":48},"2025-06-29",{"date":400,"type":19},"2025-06-27",{"date":402,"type":19},"2025-10-31",{"name":404,"class":82},"ChinaNorm",{"id":406,"slug":407,"hasResults":11,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":4,"eligibilityCriteria":411,"healthyVolunteers":11,"sex":15,"minAge":63,"maxAge":4,"enrollmentInfo":412,"targetDuration":4,"studyType":255,"phases":4,"briefSummary":413,"conditions":414,"keywords":415,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":423,"locationsCount":83},"100593747","exploring-acne-treatments-through-clinical-research-participation-100593747","NCT07010458","Exploring Acne Treatments Through Clinical Research Participation","Advancing Acne Care - Clinical Trials Open for Patient Enrollment","Inclusion Criteria:\n\n* Patients diagnosed with acne.\n* Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed\n* Subjects willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examination.\n\nExclusion Criteria:\n\n* Refusal of consent\n* Women of childbearing potential without a negative pregnancy test; or women who are lactating.\n* Any serious and\u002For unstable pre-existing medical disorders",{"count":303,"type":19},"The purpose of this study is to understand the lived experiences of acne patients enrolled in a related clinical trial testing a particular treatment. The primary focus will be on tracking trial adherence and dropout rates to enhance future research and care approaches, especially for underserved groups.",[29],[29],"2025-05-30",{"date":418,"type":48},"2025-06-08",{"date":420,"type":19},"2026-06",{"date":422,"type":19},"2028-06",{"name":424,"class":82},"Power Life Sciences Inc.",{"id":426,"slug":427,"hasResults":11,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":4,"eligibilityCriteria":431,"healthyVolunteers":91,"sex":15,"minAge":63,"maxAge":142,"enrollmentInfo":432,"targetDuration":4,"studyType":20,"phases":434,"briefSummary":435,"conditions":436,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":83},"100585974","577-nm-diode-laser-in-the-treatment-of-non--inflammatory-acne-100585974","NCT06909344","577-nm Diode Laser in the Treatment of Non -Inflammatory Acne","Effectiveness and Safety of 577-nm Diode Laser in the Treatment of Non -Inflammatory Acne","Inclusion Criteria:\n\n* Patients with acne comedones\n* Patients' ages range from 18-40 years.\n* Minimum 10 comedonal lesions on both half of the face\n\nExclusion Criteria:\n\n* Patients with systemic disease interfere with healing.\n* Patients with Photosensitivity.\n* Pregnant or lactating females.\n* Previous topical, systemic, laser, surgical treatment and comedogenic drugs in the last 3 months.\n* Skin cancer or suspicious lesions.",{"count":433,"type":19},50,[22],"The aim of this study is to evaluate the clinical efficacy and safety of the 577 nm diode laser in the treatment of non -inflammatory acne.",[29],"2025-03-27",{"date":439,"type":48},"2025-04-03",{"date":441,"type":19},"2025-03-29",{"date":443,"type":19},"2025-08-01",{"name":445,"class":55},"Al-Azhar University",{"id":447,"slug":448,"hasResults":11,"nctId":449,"briefTitle":450,"officialTitle":450,"acronym":4,"eligibilityCriteria":451,"healthyVolunteers":91,"sex":15,"minAge":63,"maxAge":452,"enrollmentInfo":453,"targetDuration":4,"studyType":20,"phases":454,"briefSummary":455,"conditions":456,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":468,"locationsCount":83},"100582846","avava-miria-general-use-100582846","NCT06868615","AVAVA MIRIA General Use","Inclusion Criteria:\n\n1. Male or female subjects between 18 to 70 years of age.\n2. Dermatologic condition that can be addressed by the laser, including but not limited to:\n\n   1. Wrinkles\n   2. Scars\n   3. Acne Scars\n   4. Active Acne\n   5. Dyschromia\n   6. Cutaneous Lesions such as Age or Sun Spots\n   7. Melasma\n   8. Laxity\n3. Willingness to have digital photographs taken of treatment area(s) and agreement with use of photographs for presentation, educational, or marketing purposes.\n4. Willingness to comply with the following during the study, including the follow-up period:\n\n   1. maintain consistent skin care regimen on treated areas.\n   2. cover treated areas or have very limited sun exposure and, if requested, use an approved sunscreen of SPF 50 or higher.\n   3. refrain from using systemic corticosteroids, according to Investigator discretion.\n   4. refrain from using topical corticosteroids, retinoids, or prescription skin-lightening medications on the treated areas, according to Investigator discretion.\n   5. refrain from any other procedures in the treatment areas.\n5. Willingness and ability to comply with study instructions and return for required visits.\n6. Subject has read and signed a written informed consent form.\n7. Subject lives within 50 miles of study site.\n8. Willingness to shave hair in intended treatment area\n\nExclusion Criteria:\n\n1. Skin pathology or condition that could interfere with evaluation of the study procedure, e.g.,\n2. Systemic treatment prescribed within previous 6 months (e.g., oral medication such as isotretinoin)\n3. Surgical treatment in the target areas within previous 6 months (e.g., laser surgery)\n4. Active vitiligo, psoriasis, or eczema in the treatment area\n5. Injection of dermal filler in the target areas within previous 1 month (e.g., collagen, hyaluronic acid filler)\n6. Cosmetic procedures in the target areas within prior 3 months (e.g., laser, microdermabrasion, skin peel)\n7. Topical treatment applied to target areas within the previous 1 month or according to Investigator discretion.\n8. Active suntan and unable or unlikely to refrain from tanning within the follow-up period.\n9. Artificial tanning in the target areas within the previous 1 month (e.g., spray, lotion, tanning bed) or intention to use artificial tanning within the follow-up period.\n10. Active localized or systemic infection, or an open wound in area being treated.\n11. Lesions in the treatment areas suspicious for malignancy (skin cancer, melanoma)\n12. History of abnormal wound healing or abnormal scarring (e.g., hypertrophic or keloid)\n13. History of connective tissue disease, such as lupus or scleroderma.\n14. Any use of medication that is known to increase sensitivity to light according to Investigator's discretion (e.g., topicals that produce sensitivity to light may be used in areas other than the target area).\n15. History of gold therapy.\n16. History of disease stimulated by heat, such as recurrent herpes simplex or herpes zoster (shingles) in the treatment area, unless treatment is conducted following a prophylactic regimen.\n17. History of radiation to the treatment area or currently undergoing systemic chemotherapy for the treatment of cancer.\n18. For Female: Pregnancy or lactation, or intent to become pregnant within the study period.\n19. Significant uncontrolled concurrent illness, such as diabetes mellitus or cardiovascular disease, e.g., uncontrolled hypertension.\n20. History of immunosuppression\u002Fimmune deficiency disorder or currently using immunosuppressive medications.\n21. Current enrollment in a clinical study of any other unapproved investigational drug or device\n22. Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect response or participation in this clinical study, or would pose an unacceptable risk to the subject.","70 Years",{"count":222,"type":19},[22],"A general protocol to treat a variety of dermatologic conditions and collect patient feedback.\n\nPrimary outcome is the collection and analysis of patient questionnaires related to the overall experience of the device treatment. Secondary outcome measures include physician and subject evaluations in regards to improvement seen in the device as well as assessment of side effects.",[29,457,374,458,459,460],"Acne Scars - Mixed Atrophic and Hypertrophic","Wrinkle","Pigment; Lesion","Skin Texture Disorder","2025-03-06",{"date":463,"type":48},"2025-03-11",{"date":465,"type":48},"2024-09-11",{"date":467,"type":19},"2027-12-30",{"name":469,"class":82},"AVAVA, Inc.",{"id":471,"slug":472,"hasResults":11,"nctId":473,"briefTitle":474,"officialTitle":474,"acronym":4,"eligibilityCriteria":475,"healthyVolunteers":11,"sex":15,"minAge":63,"maxAge":143,"enrollmentInfo":476,"targetDuration":4,"studyType":20,"phases":477,"briefSummary":478,"conditions":479,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":485,"completionDateStruct":486,"leadSponsor":488,"locationsCount":83},"100574752","clinical-evaluation-and-study-of-the-efficacy-of-a-centella-asiatica-infused-facial-mask-on-discosmetic-dermatosis-100574752","NCT06763367","Clinical Evaluation and Study of the Efficacy of a Centella Asiatica-Infused Facial Mask on Discosmetic Dermatosis","Inclusion Criteria:\n\n1. Meet mild to moderate rosacea, acne diagnostic criteria; Meet the diagnostic criteria for melasma;\n2. Over 18 years of age;\n3. Be able to follow the treatment rules of the study and be followed for 8 weeks;\n4. Informed consent; 5There were no significant cardiac, liver, kidney, gastrointestinal, neurological, psychiatric, or metabolic disorders\n\n6.No medication was used within 1 month\n\nExclusion Criteria:\n\n1. Currently pregnant, planning to become pregnant or breastfeeding;\n2. Documented hypersensitivity to any active ingredient or excipient included in the study drug, or a history of adverse reactions to cosmetic products;\n3. Participate in other clinical studies within 3 months before the start of the study;\n4. Frequent use of Chinese medicine, sleeping pills, sedatives, anti-anxiety drugs or potentially addictive substances;\n5. Present with concomitant skin conditions that may confuse the clinical assessment of rosacea, melasma, seborrheic dermatitis or pose a risk to participants, or have a history of severe skin conditions;\n6. Normal use of relevant treatment (including intense pulsed light, pulsed fuel laser, oral and topical tranexamic acid, oral tetracycline antibiotics, oral compound glycyrrhizin and other anti-inflammatory drugs)\n7. Patients with incomplete observation data, incomplete course of treatment and inability to take drugs as prescribed by doctors were removed",{"count":145,"type":19},[22],"The purpose of this study was to investigate the efficacy and safety of repairing facial mask containing Asiaticum asiatica in treating disjunctive skin diseases. A multi-center randomized double-blind self-half face control method was used. A computer-generated randomization method was used. Each cheek was randomly assigned to receive the snow glycoside mask and the control group.",[153,29,480,481],"Centella","Melasma","2025-01-02",{"date":484,"type":48},"2025-01-08",{"date":484,"type":19},{"date":487,"type":19},"2026-11-30",{"name":489,"class":55},"Nanjing First Hospital, Nanjing Medical University",{"id":491,"slug":492,"hasResults":11,"nctId":493,"briefTitle":494,"officialTitle":495,"acronym":4,"eligibilityCriteria":496,"healthyVolunteers":11,"sex":15,"minAge":497,"maxAge":498,"enrollmentInfo":499,"targetDuration":4,"studyType":20,"phases":501,"briefSummary":502,"conditions":503,"keywords":504,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":511,"startDateStruct":513,"completionDateStruct":515,"leadSponsor":517,"locationsCount":83},"100571142","a-comparative-study-of-cosmetic-product-in-subjects-with-facial-acne-during-an-associated-treatment-phase-followed-by-a-maintenance-phase-100571142","NCT06716398","A Comparative Study of Cosmetic Product in Subjects With Facial Acne During an Associated-treatment Phase Followed by a Maintenance Phase","A Randomized Investigator-blinded Comparative Study to Assess the Efficacy of the Cosmetic Care Product RV4133C - Formula JT2559 in Subjects With Facial Acne, During a 3-month-associated-treatment Phase Followed by a 3-month-maintenance Phase","Inclusion Criteria:\n\n* Male or Female aged between 14 and 24 years (included)\n* Subject with facial acne with score index severity IGA = 2 or 3, assessed on a scale ranged from 0 to 4.\n* Subject for whom a prescription of 12 weeks of a reference topical medical treatment is required from the day of the inclusion visit, for mild to moderate face acne\n\nExclusion Criteria:\n\nCriteria related to the disease:\n\n* Facial skin disease other than acne, skin abnormalities, or dermatological condition on the face liable to interfere with the study assessments\n* Acne conglobata, Acne fulminans, nodulocystic acne or acneiform eruptions, according to investigator's assessment\n* Other type of pigmentation disorder than acne-related PIH liable to interfere with the study assessments according to the investigator\n\nCriteria related to treatments and\u002For products:\n\n\\- Topical or oral treatment established or modified during the previous weeks or planned to be established or modified during the study, liable to interfere with the evaluation of the efficacy or cutaneous tolerance of the investigational products","14 Years","24 Years",{"count":500,"type":19},60,[22],"In this study, we are interested in the global benefit of the tested product as complementary care to a topical medical treatment during a 3 month-associated treatment phase followed by a 3 month-maintenance phase, compared to a light moisturizing cream, in teenagers and adults with acne. We also want to evaluate the tolerance of the tested product in association and in maintenance of the topical medical treatment.",[29],[285,505,506,507,508,509],"face","young adults","teenagers","treatment phase","maintenance","2024-11-29",{"date":512,"type":48},"2024-12-04",{"date":514,"type":48},"2024-07-03",{"date":516,"type":19},"2025-07-30",{"name":518,"class":82},"Pierre Fabre Dermo Cosmetique",{"id":520,"slug":521,"hasResults":11,"nctId":522,"briefTitle":523,"officialTitle":524,"acronym":4,"eligibilityCriteria":525,"healthyVolunteers":91,"sex":141,"minAge":63,"maxAge":117,"enrollmentInfo":526,"targetDuration":4,"studyType":20,"phases":527,"briefSummary":529,"conditions":530,"keywords":531,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":534,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":540,"locationsCount":83},"100562370","phase-2-a-full-face-study-to-evaluate-the-efficacy-of-dermapen-4-microneedling-device-in-addition-with-mg-clr-serum-for-acne-treatment-over-12-weeks-100562370","NCT06602284","A Full Face Study to Evaluate the Efficacy of Dermapen 4™ Microneedling Device in Addition with MG-CLR Serum for Acne Treatment Over 12 Weeks.","A Full Face, Baseline Controlled Study to Evaluate the Efficacy of Dermapen 4™ Microneedling Device in Conjunction with MG-CLR Serum for Acne Treatment Over 12 Weeks.","Inclusion Criteria:\n\n1. Female subjects aged between 18-45 years (both ages inclusive)\n2. Fitzpatrick skin phototype I to VI.\n3. Subjects having IGA score of 2 and 3.\n4. Subjects who have not received any kind of treatment for acne 1 month before the start of the study.\n5. Subject free of excessive hair, cuts, abrasions, fissures, wounds, lacerations, or any other skin conditions on the face.\n6. Subjects who agree not to use any other product\u002Ftreatment\u002Fhome remedy\u002F except the provided products on their face during the study period\n\nExclusion Criteria:\n\n1. Subjects with known skin condition that may impact the assessment.\n2. Subjects with active Herpes labialis infection.\n3. Subjects known to have bleeding and clotting disorders (self-declared).\n4. Subjects known to have connective tissue disorders.\n5. Subjects with any other signs of significant local irritation or skin disease.\n6. Subjects currently taking any medication, which the investigator believes may influence the interpretation of the data.",{"count":201,"type":19},[181,528],"PHASE3","This study is conducted to check how well the Dermapen 4™ microneedling device works with MG-CLR serum for treating acne over 12 weeks.",[29],[532],"dermapen, microneedling, acne","2024-09-16",{"date":535,"type":48},"2024-09-19",{"date":537,"type":19},"2024-10",{"date":539,"type":19},"2025-03",{"name":541,"class":82},"Equipmed USA LLC",{"id":543,"slug":544,"hasResults":11,"nctId":545,"briefTitle":546,"officialTitle":546,"acronym":4,"eligibilityCriteria":547,"healthyVolunteers":91,"sex":15,"minAge":63,"maxAge":4,"enrollmentInfo":548,"targetDuration":4,"studyType":20,"phases":549,"briefSummary":550,"conditions":551,"keywords":552,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":556,"startDateStruct":558,"completionDateStruct":560,"leadSponsor":562,"locationsCount":83},"100511654","the-use-of-image-based-computer-gradings-in-the-analysis-of-acne-rosacea-melasma-and-seborrheic-dermatitis-100511654","NCT05942248","The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis","Inclusion Criteria:\n\n* Adults with acne, rosacea, melasma or seborrheic dermatitis\n\nExclusion Criteria:\n\n* Prisoners\n* Adults unable to consent\n* Artificial facial markings on day of facial photography (such as piercings and tattoos) that may interfere with imaging in the opinion of the investigator",{"count":66,"type":19},[22],"The study is conducted to determine if image-based computer grading can of acne, melasma, rosacea and seborrheic dermatitis correlate well to expert based clinical severity grading.",[29,481,153,227],[553,554],"Artificial Intelligent","Skin","2024-08-26",{"date":557,"type":48},"2024-08-27",{"date":559,"type":48},"2023-06-06",{"date":561,"type":19},"2025-02-28",{"name":563,"class":82},"Integrative Skin Science and Research",{"id":565,"slug":566,"hasResults":11,"nctId":567,"briefTitle":568,"officialTitle":569,"acronym":4,"eligibilityCriteria":570,"healthyVolunteers":91,"sex":15,"minAge":63,"maxAge":4,"enrollmentInfo":571,"targetDuration":4,"studyType":20,"phases":573,"briefSummary":574,"conditions":575,"keywords":576,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":580,"lastUpdatePostDateStruct":581,"startDateStruct":583,"completionDateStruct":585,"leadSponsor":587,"locationsCount":83},"100551733","evaluation-of-effaclar-duom-on-acne-lesions-in-subjects-with-mild-to-moderate-acne-on-face-and-trunk-100551733","NCT06463925","Evaluation of Effaclar Duo+M on Acne Lesions in Subjects With Mild to Moderate Acne on Face and Trunk","Evaluation of Effaclar Duo+M on Inflammatory and Non-Inflammatory Lesions in Subjects With Mild to Moderate Acne on Face and Trunk (Back and Chest)","Inclusion Criteria:\n\n* phototype I to VI\n* mild to moderate acne on the face and trunk\n\nExclusion Criteria:\n\n* cutaneous pathology on the studied zone other than acne\n* topical or systemic treatment during the previous weeks liable to interfere with the assessment of the acceptability and efficacy of the studied products",{"count":572,"type":19},65,[22],"This single-center, open, non-randomized study aims the efficacy evaluation of Effaclar Duo+M and Effaclar+M Purifying foaming gel on total acne lesion count, pigmented lesions and scars for 6 months in subjects with mild to moderate facial and truncal acne.",[29],[577,578,579],"facial and truncal acne","Effaclar Duo+M","acne lesions","2024-06-14",{"date":582,"type":48},"2024-06-18",{"date":584,"type":48},"2023-12-07",{"date":586,"type":19},"2024-09",{"name":588,"class":82},"Cosmetique Active International",{"id":590,"slug":591,"hasResults":11,"nctId":592,"briefTitle":593,"officialTitle":593,"acronym":4,"eligibilityCriteria":594,"healthyVolunteers":11,"sex":15,"minAge":63,"maxAge":595,"enrollmentInfo":596,"targetDuration":4,"studyType":20,"phases":598,"briefSummary":599,"conditions":600,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":602,"lastUpdatePostDateStruct":603,"startDateStruct":605,"completionDateStruct":607,"leadSponsor":609,"locationsCount":83},"100540057","phase-2-study-to-evaluate-the-efficacy-safety-and-tolerability-of-photodynamic-therapypdt-with-chlorin-e6-in-treating-moderate-to-severe-acne-100540057","NCT06311890","Study to Evaluate the Efficacy, Safety and Tolerability of Photodynamic Therapy(PDT) With Chlorin-e6 in Treating Moderate to Severe Acne","Inclusion Criteria:\n\n1. Subject is male or non-pregnant female 18 years of age and younger than 50 years of age.\n2. Subject has moderate to severe facial acne vulgaris.\n3. Subject has provided written informed consent.\n\nExclusion Criteria:\n\n1. People who are taking photosensitive drugs;\n2. Allergic to any component of the photosensitizer;\n3. porphyrins or allergies to porphyrins, with a history of photosensitivity;\n4. Pregnant or lactating women and those planning to become pregnant within 3 months;\n5. Oral or topical antibiotics, retinoids, glucocorticoids, peroxybenzoyl and other drugs within the past 1 month;\n6. Have a history of exposure to sunlight in the past 1 month, have received photoelectric treatment in the past 3 months, or have received facial grinding treatment in the past six months;\n7. are using vasodilators (such as nitroglycerin, etc.), beta blockers (such as metoprolol, etc.), anticoagulants (such as warfarin, etc.) and other drugs that easily cause facial capillary dilatation;\n8. Patients with facial rosacea, atopic dermatitis, hormone-dependent dermatitis and other facial skin-related diseases;\n9. Abnormal blood and urine routine, liver and kidney function, diseases of important organs and hematopoietic system that researchers believe are not suitable for clinical trials;\n10. Patients participating in other clinical trials at the same time.","50 Years",{"count":597,"type":19},46,[181],"This study aims to evaluate the clinical efficacy, safety and tolerability of a photodynamic therapy(PDT) based on a new photosensitizer, Chlorin-e6, in the treatment of moderate to severe acne. The hypothesis is that the therapy has good efficacy, safety and tolerability.",[29,601],"Photodynamic Therapy","2024-03-13",{"date":604,"type":48},"2024-03-15",{"date":606,"type":48},"2024-02-01",{"date":608,"type":19},"2026-09-30",{"name":610,"class":55},"Xiyuan Hospital of China Academy of Chinese Medical Sciences"]